Alessandra Fabi

Clinical characteristics and drug-drug interactions in human epidermal growth factor receptor 2-positive breast cancer treated with trastuzumab deruxtecan: real-world data from the DE-REAL study.

Interplay Between HER2-Low Status, Hormone Receptor Expression, and Therapeutic Response to Cyclin-Dependent Kinase 4/6 Inhibitors as First-Line Treatment in Luminal-like Metastatic Breast Cancer: The CYCLHER Study

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer

Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world

Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy.

Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives on Primary Sarcomas and Malignant Phyllodes Tumors.

Sexual health in cancer care: a narrative review and position statement from the Italian Association of Medical Oncology (AIOM).

Argo Delphi consensus statement on red flags and clinical gateways towards rare disease diagnosis

LBA20 Primary results from ASCENT-03: A randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (chemo) in patients (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i)

Validation of the FACIT-Fatigue scale in patients with locally advanced or metastatic breast cancer.

Pregnancy vs. Postpartum Breast Cancer: Distinct Tumor Biology and Survival Trends in a Contemporary Cohort.

Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab.

Digital integration of narrative medicine and patient-reported outcome measures to improve understanding of quality of life in metastatic breast cancer: the PERGIQUAL study.

A New Model for Bone Health Management in Postmenopausal Early Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy-The Predict & Prevent Project.

HER2-Driven Breast Cancer: Role of the Chaperonin HSP90 in Modulating Response to Trastuzumab-Based Therapeutic Combinations.

Lifestyle and environmental factors in women carrying BRCA pathogenic variants with and without cancer.

Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials

Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study

Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.

Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial.

Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer.

Outcomes of Radiotherapy in Oligoprogressive Breast Cancer.

Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study

Trastuzumab deruxtecan in patients with breast cancer with brain metastases: The DE-REAL study.

Preventing Bone Loss in Breast Cancer Patients: Designing a Personalized Clinical Pathway in a Large-Volume Research Hospital.

Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.

Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study.

Long-Term Safety of Level II Oncoplastic Surgery after Neoadjuvant Treatment for Locally Advanced Breast Cancer: A 20-Year Experience.

Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer: insights from real-world data of a nationwide cohort

Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings.